Psoriasis: An update on topical therapies


New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium. Additional noteworthy developments include new fixed combinations and new molecules under development.

RELATED: IL-23 inhibitors may offer psoriasis patients longer-lasting results

The polyaphron dispersion (PAD) vehicle platform (MC2 Biotek) includes 10 to 30 times less surfactants than other emulsions, which makes it less irritating, says Leon Kircik, M.D. He is clinical professor of dermatology, Icahn School of Medicine at Mount Sinai, New York; associate clinical professor of dermatology, Indiana University Medical Center; and Medical Director, Physicians Skin Care, PLLC, and Skin Sciences, PLLC, in Louisville, KY.

PAD technology also uses a robust lipid shell that allows high stability in aqueous environments.

“So now you have a less irritating, more durable vehicle,” he adds.

In phase 3, the combination of calcipotriene and betamethasone diproprionate in the PAD vehicle (Enstilar foam, LEO Pharma) proved superior to a calcipotriene-betamethasone topical suspension ointment (Taclonex, LEO Pharma). The proportions of patients who were clear or nearly clear with at least a two-point improvement over baseline were 40% for the foam versus 22% for ointment.


Dr. Kircik has served as an investigator, speaker, advisor or consultant for Amgen, Celgene, Clarify, Dermavant, LEO and MC2 Biotek.


Leon Kircik, M.D. “Topical Therapies for Psoriasis,” South Beach Symposium. February 8, 2020.

Source link


Please enter your comment!
Please enter your name here